Balaxi Pharmaceuticals (BALAXI) Q4 14/15 earnings summary

Executive summary

• FY15 net profit was Rs 1,023,544, down from Rs 1,095,288 in FY14; gross income rose to Rs 2,412,280 from Rs 1,929,173.

• Operations focused on investment and trading; all activity was reported in one investment segment.

Financial highlights

• Audited total revenue was Rs 24,122.80 hundred in FY15 vs Rs 19,291.73 hundred in FY14; operating revenue fell to Rs 12,374.47 hundred from Rs 14,276.88 hundred.

• Other income increased to Rs 11,748.33 hundred from Rs 5,014.85 hundred, led by mutual fund income of Rs 4,211.68 hundred and bank interest of Rs 7,135.21 hundred.

• PBT was Rs 1,471,464 vs Rs 1,489,288; PAT was Rs 1,023,544 vs Rs 1,095,288.

• Employee benefit expense rose to Rs 2,450 hundred from Rs 930 hundred; other expenses increased to Rs 5,421.46 hundred from Rs 2,426.92 hundred.

Outlook and guidance

• Management was assessing new investment avenues and anticipated growth in the domestic investment sector, citing economic growth and the Make in India campaign.

• Funds remained deployed in bank deposits and share investments while directors considered proposals to strengthen the financial base and possible business ventures.